Skip to main
EXEL

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 33%
Buy 22%
Hold 44%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis Inc. is poised for a positive outlook primarily due to the strong market positioning of its lead compound, cabozantinib, which continues to demonstrate effectiveness as a leading tyrosine kinase inhibitor (TKI) in renal cell carcinoma (RCC) through long-term data from the CHECKMATE-9ER trial. The company has also expanded the label for cabozantinib, offering new opportunities in neuroendocrine tumors (NETs), indicating potential for revenue growth and market penetration. Furthermore, ongoing successes in indications such as hepatocellular carcinoma (HCC) and management's optimism about continued improvements in treatment outcomes enhance the overall attractiveness of Exelixis’s portfolio.

Bears say

Exelixis Inc faces significant financial challenges, particularly due to an anticipated 80% drop in revenues by 2032 as a result of the impending patent cliff, which analysts believe the market has not fully accounted for. Key risks that contribute to this negative outlook include potential erosion of market share for cabozantinib in renal cell carcinoma and the lack of traction in neuroendocrine tumors, alongside disappointing clinical data for the pipeline drug zanzalintinib. Furthermore, the likelihood of generic competition further compounds these risks, suggesting that the company may struggle to maintain its revenue streams in the coming years.

Exelixis (EXEL) has been analyzed by 18 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 22% recommend Buy, 44% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Buy based on their latest research and market trends.

According to 18 analysts, Exelixis (EXEL) has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $45.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $45.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.